Issuances | Health Technology Assessment Division

Preliminary Recommendation for the Inclusion of Vasopressin 20 IU/mL (IM/IV)

Posted on February 11, 2022

Document link: Preliminary Recommendation on Vasopressin (Proponents may submit appeals to hta@doh.gov.ph until 25 February 2022.) Document Preview:

[Department Circular No. 2022- 0074] Nomination to the Health Technology Assessment Council (HTAC) Subcommittee on Drugs

Posted on February 9, 2022

[Department Circular No. 2022- 0015] Health Technology Assessment Council (HTAC) Recommendation to Include Sambong 250mg Tablet in the Philippine National Formulary

Posted on January 21, 2022

Preliminary Recommendation for the Non-Inclusion of Pertuzumab for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Posted on January 20, 2022

Document link: Preliminary Recommendation on Pertuzumab for HER2+ breast cancer (Proponents may submit appeals to hta@doh.gov.ph until 04 February 2022.) Document Preview:

[Department Personnel Order No. 2021-3184] Appointment of the New Member of the Health Technology Assessment Council Subcommittee on Preventive and Promotive Health

Posted on January 5, 2022

Read more here: ALETH THERESE L. DACANAY, PH.D